Oncolytic virus cancer therapy Market: Epidemiology, Therapies, Companies, DelveInsight | Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology

Oncolytic virus cancer therapy therapies, such as IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, and others, are expected to boost the Oncolytic virus cancer therapy Market in the upcoming years.

DelveInsight has launched a new report on "Oncolytic virus cancer therapy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Oncolytic virus cancer therapy, historical and forecasted epidemiology as well as the Oncolytic virus cancer therapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Oncolytic virus cancer therapy market report @ https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Oncolytic virus cancer therapy Market Report:

The United States dominates the oncolytic virus market, contributing over 70% of its total size, far surpassing regions like the EU4, UK, and Japan. Oncolytic viruses offer key advantages over other cancer immunotherapies, including strong tumor-killing ability, targeted action, and fewer side effects or resistance issues.
Currently, only two therapies-IMLYGIC (Amgen, approved in 2015) and DELYTACT (Daiichi Sankyo, approved in 2021)-are approved globally. The development pipeline remains strong, with companies like Replimune, Genelux, Imugene, and EpicentRx leading innovation. RP1 stands out as a frontrunner, projected to hold around 40% of the market in the next decade.
Notably, in November 2023, the FDA granted Fast Track designation to Genelux's Olvi-Vec for treating platinum-resistant/refractory ovarian cancer.
GLOBOCAN data indicates that new breast cancer cases in the United States are projected to increase from 274,375 in 2022 to 321,295 by 2035. DelveInsight's analysis also shows that, in 2023, prostate cancer made up around 20% of the total eligible patient population for oncolytic virus therapies across the seven major markets (7MM).
Key Oncolytic virus cancer therapy companies such as Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, and others are evaluating new drugs for Oncolytic virus cancer therapy to improve the treatment landscape.
Promising Oncolytic virus cancer therapy therapies include IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, and others.

Oncolytic virus cancer therapy Overview

Oncolytic viruses are a unique type of cancer therapy that work by selectively replicating within tumor cells, triggering immunogenic cell death, and activating the body's immune response against cancer. These viruses-either naturally occurring or genetically modified-specifically target and destroy cancer cells.

Though not fully understood, they act through two main pathways: directly breaking down tumor cells (oncolysis) and indirectly boosting the body's immune defense against tumors.

They can be classified as RNA or DNA viruses. RNA viruses-such as reoviruses, paramyxoviruses, and picornaviruses-replicate quickly and rapidly kill tumor cells but have limited genetic capacity. In contrast, DNA viruses like herpesviruses, adenoviruses, and poxviruses replicate more slowly but can carry multiple inserted genes, allowing for more complex therapeutic strategies.

Oncolytic virus cancer therapy Market Outlook

As cancer remains a leading global cause of death, the demand for innovative treatments is intensifying. Oncolytic viruses (OVs), which selectively infect and destroy cancer cells while activating the immune system, have gained attention as a promising therapeutic strategy. Market growth is being fueled by increased R&D efforts, rising pharmaceutical investments, and a growing number of clinical trials.

The field saw major milestones with the FDA and European approval of IMLYGIC (Amgen) in 2015 for unresectable melanoma, and Japan's conditional approval of DELYTACT (Daiichi Sankyo) in 2021 for malignant glioma. These approvals showcased the clinical potential of genetically engineered viruses to both kill tumors and stimulate immune responses.

While these approvals mark significant progress, ongoing clinical trials by companies like Replimune, DNAtrix, and SillaJen continue to expand the potential of OVs across multiple cancer types, reinforcing their future role in personalized oncology.

Discover how the Oncolytic virus cancer therapy market is rising in the coming years @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Oncolytic Virus Marketed Drugs

IMLYGIC (T-VEC): Amgen
DELYTACT (G47Δ): Daiichio Sankyo

Oncolytic virus cancer therapy Emerging Drugs
Olvi-Vec: Genelux
RP1: Replimune

Scope of the Oncolytic virus cancer therapy Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Oncolytic virus cancer therapy Companies: Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, and others
Key Oncolytic virus cancer therapy Therapies: IMLYGIC (T-VEC), DELYTACT (G47Δ), Olvi-Vec, RP1, and others
Oncolytic virus cancer therapy Therapeutic Assessment: Oncolytic virus cancer therapy current marketed and Oncolytic virus cancer therapy emerging therapies
Oncolytic virus cancer therapy Market Dynamics: Oncolytic virus cancer therapy market drivers and Oncolytic virus cancer therapy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Oncolytic virus cancer therapy Unmet Needs, KOL's views, Analyst's views, Oncolytic virus cancer therapy Market Access and Reimbursement

To know what's more in our Oncolytic virus cancer therapy report, visit https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Oncolytic virus cancer therapy Market Report:
Oncolytic virus cancer therapy market report covers a descriptive overview and comprehensive insight of the Oncolytic virus cancer therapy Epidemiology and Oncolytic virus cancer therapy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Oncolytic virus cancer therapy market report provides insights into the current and emerging therapies.
The Oncolytic virus cancer therapy market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Oncolytic virus cancer therapy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Oncolytic virus cancer therapy market.

Got queries? Click here to know more about the Oncolytic virus cancer therapy market Landscape https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Oncolytic virus cancer therapy Patient Share (%) Overview at a Glance
5. Oncolytic virus cancer therapy Market Overview at a Glance
6. Oncolytic virus cancer therapy Disease Background and Overview
7. Oncolytic virus cancer therapy Epidemiology and Patient Population
8. Country-Specific Patient Population of Oncolytic virus cancer therapy
9. Oncolytic virus cancer therapy Current Treatment and Medical Practices
10. Unmet Needs
11. Oncolytic virus cancer therapy Emerging Therapies
12. Oncolytic virus cancer therapy Market Outlook
13. Country-Wise Oncolytic virus cancer therapy Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Oncolytic virus cancer therapy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Oncolytic virus cancer therapy Market Outlook 2034 https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Oncolytic virus cancer therapy Pipeline Insights, DelveInsight

"Oncolytic virus cancer therapy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oncolytic virus cancer therapy market. A detailed picture of the Oncolytic virus cancer therapy pipeline landscape is provided, which includes the disease overview and Oncolytic virus cancer therapy treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.